Jasper Therapeutics, Inc.

JSPR

US4718712023

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 11:05:30 2024-07-08 EDT			5-day change	1st Jan Change
22.56 ^USD	+6.72%		-2.57%	+185.74%

01:43pm	BTIG Initiates Jasper Therapeutics at Buy With $90 Price Target	MT
07-01	Jasper Therapeutics, Inc.(NasdaqCM:JSPR) added to Russell Small Cap Completeness Index	CI

Jasper Therapeutics, Inc.(NasdaqCM:JSPR) added to Russell Small Cap Comp Growth Index

July 30, 2024

Latest news about Jasper Therapeutics, Inc.

BTIG Initiates Jasper Therapeutics at Buy With $90 Price Target	07:43am	MT
Jasper Therapeutics, Inc.(NasdaqCM:JSPR) added to Russell Small Cap Completeness Index	06-30	CI
Jasper Therapeutics, Inc.(NasdaqCM:JSPR) added to Russell 2000 Index	06-30	CI
Jasper Therapeutics, Inc.(NasdaqCM:JSPR) added to Russell 3000E Index	06-30	CI
Jasper Therapeutics, Inc.(NasdaqCM:JSPR) added to Russell 2500 Growth Index	06-30	CI
Jasper Therapeutics, Inc.(NasdaqCM:JSPR) added to Russell 3000E Growth Index	06-30	CI
Jasper Therapeutics, Inc.(NasdaqCM:JSPR) added to Russell 3000 Growth Index	06-30	CI
Jasper Therapeutics, Inc.(NasdaqCM:JSPR) added to Russell 2000 Growth Index	06-30	CI
Jasper Therapeutics, Inc.(NasdaqCM:JSPR) added to Russell 2000 Dynamic Index	06-30	CI
Jasper Therapeutics, Inc.(NasdaqCM:JSPR) added to Russell Small Cap Comp Growth Index	06-30	CI
Jasper Therapeutics, Inc.(NasdaqCM:JSPR) added to Russell 2500 Index	06-30	CI
Jasper Therapeutics, Inc.(NasdaqCM:JSPR) added to Russell 3000 Index	06-30	CI
Stifel Initiates Jasper Therapeutics at Buy With $86 Price Target	06-27	MT
Jasper Therapeutics, Inc. Announces Board Changes	06-19	CI
Jasper Therapeutics, Inc. Presents Data from Preclinical Briquilimab Study at the 2024 EHA Hybrid Congress	06-14	CI
Jasper Therapeutics, Inc. to Present Data on Briquilimab in Mast Cell Driven Diseases at the EAACI Congress 2024	05-30	CI
Transcript : Jasper Therapeutics, Inc. - Special Call	05-20
Jasper Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-14	CI
Jasper Therapeutics to Expand Mast Cell Portfolio, Initiates Asthma Study in Q4	05-13	MT
Asper Therapeutics, Inc Announces the Expansion of its Mast Cell Development Portfolio with Phase 1b/2a Study Evaluating Briquilimab in Asthma Patients	05-13	CI
Certain Restricted Stock Units of Jasper Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 7-MAY-2024.	05-06	CI
Certain Stock Options of Jasper Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 7-MAY-2024.	05-06	CI
Certain Common Stock of Jasper Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 7-MAY-2024.	05-06	CI
HC Wainwright Starts Jasper Therapeutics With Buy Rating, $65 Price Target	05-06	MT
Evercore ISI Initiates Jasper Therapeutics With Outperform Rating, Price Target is $65	04-03	MT

Chart Jasper Therapeutics, Inc.

Duration

Period

More charts

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics targeting mast cell driven diseases, such as Chronic Spontaneous Urticaria (CSU) and Chronic Inducible Urticaria (CIndU). It also has ongoing programs in diseases where targeting diseased hemopoietic stem cells can provide benefits, such as Lower to Intermediate Risk Myelodysplastic Syndrome (LR-MDS), and stem cell transplant conditioning regimens. The Company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (c-Kit) receptor on mast and stem cells. The SCF/c-Kit pathway is a survival signal for mast cells. It is also developing briquilimab as a one-time conditioning therapy for severe combined immunodeficiency (SCID) patients undergoing a second stem cell transplant for which it is conducting a Phase 1/2 clinical trial.

Sector

Pharmaceuticals

Calendar

2024-08-08 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

21.14 USD

Average target price

66.14 USD

Spread / Average Target

+212.88%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
JASPER THERAPEUTICS, INC.	+185.74%	319M
ELI LILLY AND COMPANY	+58.63%	823B
JOHNSON & JOHNSON	-6.50%	353B
MERCK & CO., INC.	+16.59%	320B
ABBVIE INC.	+7.97%	295B
ASTRAZENECA PLC	+13.94%	239B
NOVARTIS AG	+14.78%	220B
ROCHE HOLDING AG	-0.41%	219B
AMGEN INC.	+9.00%	167B
PFIZER, INC.	-3.00%	159B

Other Pharmaceuticals